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long-term clinical benefits and cost-offsets of oral dia-
betic management with nateglinide in combination with
metformin vs. metformin alone in the Netherlands.
METHODS: Data from clinical trials and epidemiologi-
cal studies have been incorporated in a diabetes model
that dynamically relates patient characteristics (demo-
graphics, cardiovascular risk factors, diabetes history)
and glycemic control to diabetic complications. In the
model, a cohort of 10,000 patients was followed over a
30-year period for the occurrence of diabetic complica-
tions, its associated treatment costs and mortality. The
impact of improved glycemic control (HbA1c and post-
prandial glucose or PPG) was modeled using results from
a clinical trial.
RESULTS: An incremental reduction in HbA1c of 0.7%
and of PPG by 1.4mmol/L of nateglinide combination
therapy will reduce the number of patients with end-stage
renal disease (ESRD), blindness and lower-extremity am-
putation by 168, 169 and 197 respectively. Another 78
cases of AMI and 38 cases of cerebral stroke will be
avoided. This will result in cost-offsets of NLG 6,527 per
patient on average, mainly due to ESRD (72%), stroke
(6%), amputation (6%) and blindness (5%). The esti-
mated life expectancy increases by 0.33 years (0.2 years if
discounted at 4%). The model was robust for changes in
critical assumptions.
CONCLUSION: Improved glycemic control as achieved
with combination therapy of nateglinide plus metformin
will substantially reduce the number of diabetic compli-
cations and associated treatment costs over treatment
with metformin alone in the Netherlands.
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OBJECTIVES: To assess antidiabetic treatment and asso-
ciated costs of patients with type 2 diabetes in Germany.
METHODS: In a cost-of-illness study based on a repre-
sentative sample of 809 patients with type 2 diabetes,
treatment strategies, overall resource use and cost were
investigated for the year 1998. This analysis is centred on
the question of how the antidiabetic treatment influences
resource use and cost. Taking the perspective of the statu-
tory health insurance, overall direct and indirect health-
care costs for diabetes patients were investigated.
RESULTS: Among all patients, 19% were treated with
diet and exercise only, 53% received oral anti-diabetics
(OAD) and 28% were insulin recipients. The three treat-
ment groups differed in terms of time since diagnosis of
diabetes and complication status, with the most severe
cases in the insulin group. Total costs were highest for
patients taking insulin and amounted to 4,100 Euro. For
patients on diet/exercise and on OAD, total costs were
2242 Euro and 2184 Euro, respectively. Similarly, the
cost of medication was also highest for patients taking in-
sulin (1296 Euro) compared to patients on OAD (576
Euro) or diet (484 Euro). The cost of hospitalization and
rehabilitation was approximately half the total cost in
each group (insulin 2166 Euro, OAD 1105 Euro, diet
1047 Euro). Patients on diet had similar total and inpa-
tient costs as patients on OAD, but had the highest indi-
rect cost. A regression analysis was used to determine the
influence of treatment type, time since diagnosis of diabe-
tes, and complication status on total costs. Insulin treat-
ment and complication status had a significant impact
(p  .0001) on total costs whereas time since diagnosis
and other treatment types had none.
CONCLUSIONS: The disease progression is reflected by
the change in antidiabetic treatment. The highest costs
were observed in patients treated with insulin. These pa-
tients also experience more severe complications.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) in combination therapy versus usual care for
patients with type 2 diabetes.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics was adapted to simulate long-
term management, health outcomes, resource utilisation
and treatment costs of patients with type 2 diabetes. The
model accounts for most complications occurring in dia-
betes patients: nephropathy; retinopathy; acute myocar-
dial infarction; angina pectoris; stroke, and amputation.
The analysis was done from a third-party-payer perspec-
tive and costs figured relative to the year 2000. A 3% dis-
count rate was applied to costs and outcomes and sensi-
tivity analysis was performed to test the results.
RESULTS: PIO 30 mg in combination with metformin
(MF) was associated with a longer life expectancy (14.06
years) than sulphonylureas (SU)/MF (13.49 years) or
rosiglitazone (RSG) 8 mg/MF (13.98 years). PIO-based
combinations were associated with the lowest number of
complications and deaths. For every 38 patients treated
with PIO 30 mg/MF rather than SU/MF or every 37 pa-
tients, respectively, for PIO 15 mg/SU rather than MEF/SU,
one complication was avoided. Also, for every 39 patients
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treated with PIO 30 mg/MF rather than SU/MF, one
death was avoided (after 15 years of treatment). PIO was
more expensive, but this was in part offset by a reduction
in complications. The average undiscounted patient life-
time additional cost of treatment with PIO combinations
over their alternatives ranges from 9421 Denmark Kroner
(DKK) to a maximum of 74,687DKK. The incremental cost
per life year gained of PIO 30 mg/MF relative to SU/MF,
and RSG 8 mg/MF is 208,657DKK and 167,060DKK,
respectively.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type 2 diabetes and repre-
sents a cost-effective use of scarce resources when judged
against other therapeutic interventions. It is necessary to
confirm the results of this theoretical model once long-
term effectiveness data with the compared alternatives
are available.
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OBJECTIVES: The treatment of diabetic foot ulcers is
extremely costly and such ulcers have potentially pro-
found consequences for the patient. Apligraf, a living hu-
man skin equivalent, has been shown in clinical trials to
be effective in the management of DFUs resistant to stan-
dard care. However, such trials provide little or no infor-
mation about long-term costs. We attempt to estimate the
costs of treatment in the Netherlands with standard care
and the cost-effectiveness of Apligraf.
METHODS: A Markov chain model was developed to
compare the treatment costs of standard care (good
wound care) with Apligraf for treatment of diabetic foot
ulcers. The states in the model relate to the condition of
the ulcer and the amputation status of the patient. Tran-
sition probabilities were calculated using data from the
Apligraf DFU pivotal study and other published litera-
ture. Cost data were drawn from a number of sources in
the Netherlands.
RESULTS: The monthly cost of treating an uninfected ul-
cer is 432 Euros, while treating an infected or gangrenous
ulcer costs 1963 and 2359 Euros per month, respectively.
Amputation costs range from 7582 Euros (toe) to 15,810
Euros (whole foot). For patients receiving good wound
care, the annual cost of care is 4775 Euros. The results
suggest that costs incurred in using Apligraf are recov-
ered within about a year of initiating treatment. Patients
receiving Apligraf experience improved healing rates and
fewer amputations. As a result, Apligraf was more cost-
effective than good wound care.
CONCLUSION: Apligraf promises to be a cost-effective
treatment for patients with DFU resistant to normal care.
More rapid healing and reduced number of amputations
mean that patients will have a better quality of life. Fur-
ther studies are needed to examine the long-term costs
and effects of Apligraf.
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OBJECTIVES: Treatment costs for type 2 diabetic pa-
tients in Germany amount to more than 31 billion DM
per year, mainly because of related complications. In ac-
cordance with the St. Vincent declaration, these compli-
cations should be reduced at least by one third by treat-
ing according to current guidelines.
METHODS: The CODE-2 study results described the ac-
tual treatment of diabetic patients and associated costs. This
analysis focuses on those 47% of diabetic patients who had
no complications, with the aim of preventing long-term
complications in these patients. The European Diabetes Pol-
icy Group guidelines were applied to define the optimal
therapy regarding blood glucose, lipids and blood pressure.
Costs of guideline-related medication (antidiabetic, lipid
lowering agents and antihypertensive drugs) and costs of ad-
ditional outpatient treatment were calculated using official
tariffs. These results were compared to the cost of current
treatment as assessed in CODE-2.
RESULTS: Guideline treatment would induce 1270 DM
cost per patient for additional medication and outpatient
treatment. For office-based physicians who treat nearly
10% of their patients for diabetes, that would mean a
budget increase of nearly 90,000 DM per year for each
physician. Thus, for all of Germany annually about 2.1
billion DM would have to be invested in diabetes patients
who do not have complications.
CONCLUSIONS: Treatment of patients with type 2 dia-
betes according to the guidelines makes a huge invest-
ment necessary. Nevertheless, this could be balanced by
avoiding long-term complications in the future. Assum-
ing optimal treatment according to guidelines could pre-
vent one third of late diabetes-related complications and
by using the published data of the CODE-2 study, poten-
tial cost savings of 2.9 billion DM could be achieved,
which actually exceeds the cost of prevention.
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